Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety,
tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2
dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Age: 18 years - 66+
Gender: All
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors
including urothelial cancer. The study is conducted in two parts - phase Ia
(dose-escalation, dose-o...
Age: 18 years - 66+
Gender: All
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD)
in the following tumor types: endometrial cancer (EC); head and neck squamous cell
carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC);
hepatocel...
Age: 18 years - 66+
Gender: All
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study
to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080
monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1
inhibitor), cetuxim...
Age: 18 years - 66+
Gender: All
